GSK’s crown jewels need to start sparkling

GSK needed to impress with the first results after spinning off its consumer arm, and a lift to full-year guidance was duly delivered today. Shares in the UK group have recovered strongly since early 2021, when they hit a 10-year low on concerns about the pipeline and its ability to pay a dividend. That recovery now needs to be supported by data, and the remainder of 2022 holds some big readouts. These concern several of the “crown jewels” that carry £20bn in peak sales potential, as forecast by the company last year. The RSV reveal is most important; GSK has already toplined this as positive but full details remain crucial. Elsewhere, the sellside has relatively high hopes for otilimab, which counts as GSK’s second most valuable pipeline project behind the RSV candidate, according to Evaluate Pharma. Failures with other anti-GM-CSF MAbs should be noted, however. A big expansion of depemokimab's pivotal programme was also revealed today; the long-acting anti-IL-5 MAb is a Nucala follow-on for severe asthma. Data are unlikely before late 2023, but the big investment here makes it a project to watch.

A big second half for new GSK: key readouts due before year end 
Project Details Key trials
GSK3844766A Adjuvanted RSV vaccine for older adults Presentation of ph3 Aresvi trial in adults ≥60 (toplined positive Jun 2022) and other supportive ph3 studies
Bepirovirsen Hep B antisense project (licensed from Ionis) Final results from the monotherapy trial B-Clear*
Gepotidacin Novel antibiotic (topoisomerase inhibitor) Interim results from ph3 trials Eagle-2 and Eagle-3 (females with uUTI/acute cystitis)
MenABCWY First-generation pentavalent (5-in-1) meningococcal vaccine Pivotal results in healthy young adults (MenABCWY – V72 72)
Otilimab Anti-GM-CSF MAb Readout from pivotal RA trials Contrast-1, Contrast-2 and Contrast-3
Blenrep Anti-BCMA ADC  Readout of pivotal Dreamm-3 trial in relapsed/refractory multiple myeloma
Jemperli Anti-PD-1 MAb (from Tesaro) Readout from pivotal Ruby trial in 1L stage III or IV endometrial cancer
*Interim results were presented at EASL 2022. uUTI=uncomplicated urinary tract infections. Source: company communication. 

Share This Article